Grant information
- NIH R01CA257837
04/01/2021 – 03/31/2025
My lab develops polymeric nanomedicines for ratiometric drug delivery. By poly(ethylene glycol)‑block‑poly(lactic acid) nanocarriers and oligo(lactic acid) prodrug chemistry, we normalize drug physicochemical properties and co‑deliver drug combinations at fixed ratio to sustain and synchronize exposure at tumors. A PEG‑assist, solvent‑free fabrication method provide scalable, reproducible PEG-b-PLA nanomedicines with high drug loading efficiency toward IND‑enabling studies. In aggressive cancers such as triple‑negative breast cancer, this strategy yields meaningful improvements in efficacy and safety relative to conventional formulations, developing “nano‑better” therapies.